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This brief review summarises recent observations which suggest a possible mechanism for organophosphate-
induced delayed neuropathy (OPIDN). Neuropathy target esterase (NTE) has been shown to deacylate 
endoplasmic reticulum (ER) membrane phosphatidylcholine (PtdCho). Raised levels of PtdCho are present 
in the brains of swiss cheese/NTE mutant Drosophila together with abnormal membrane structures, axonal 
and dendritic degeneration and neural cell loss. Similar vacuolated pathology is found in the brains of mice 
with brain-specific deletion of the NTE gene and, in old age, these mice show clinical and histopathological 
features of neuropathy resembling those in wild-type mice chronically dosed with tri-ortho-cresylphosphate. 
It is suggested that OPIDN results from the loss of NTE’s phospholipase activity which in turn causes ER 
malfunction and perturbation of axonal transport and glial-axonal interactions. 
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During the 20th century, thousands of people 
were paralysed by accidental ingestion of tri-ortho-
cresylphosphate (TOCP). The same paralysis 
was present in rare cases of poisoning by some 
organophosphorus (OP) insecticides. OP-induced 
delayed neuropathy (OPIDN) has been studied 
experimentally in chickens, and features a latent period 
of at least one week before the onset of progressive 
hind limb ataxia and paralysis accompanied by distal 
degeneration of long nerves in the spinal cord and 
legs (1, 2). Neuropathic OPs inhibit the ability of brain 
homogenates to catalyse hydrolysis of an artificial 
ester substrate and this enzyme activity is called 
NTE (3, 4). However, the events linking NTE to axon 
degeneration were enigmatic until molecular cloning 
of NTE (5) allowed new experimental approaches.
The biochemical function of NTE
Studies in mammalian cell lines and yeast have 
shown that NTE is anchored to the cytoplasmic face 
of the endoplasmic reticulum (ER) where it catalyses 
the deacylation of phosphatidylcholine (PtdCho) to 
glycerophosphocholine (6, 7) (Figure 1). PtdCho 
comprises up to 50 % of the phospholipid content of 
eukaryotic cell membranes and thus NTE plays a major 
role in membrane homeostasis. PtdCho accumulates 
in, and NTE activity is absent from, the brains of swiss 
cheese mutant Drosophila and this is accompanied by 
membrane abnormalities, axonal/dendrite degeneration 
and brain vacuolation (8). Likewise, in mice with brain-
specific NTE deletion, prominent vacuolation of the 
hippocampus and thalamus is evident between 2 to 5 
months of age (9).
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Species susceptibility to OPIDN
In large animals (humans, cattle, cats, chickens) 
a single dose of neuropathic OP causes ataxia and 
paralysis within 1 to 3 weeks. By contrast, rodents, 
and particularly mice, are refractory to OPIDN. A few 
swollen axons in the brain stem of mice were detected 
three weeks after a single dose of TOCP, but no clinical 
signs or axonal degeneration (10). However, dosing 
mice with TOCP daily for 9 months induced axonal 
degeneration and hind-limb paralysis (11). Finally, 
brain-specific NTE knock-out mice exhibit progressive 
axonal degeneration and hind-limb ataxia between 6 
to 12 months of age (Read et al, unpublished).
Non-neuropathic inhibitors of NTE
Carbamates such as pyridostigmine have been 
used to protect humans and animals from imminent 
exposure to OP nerve agents. The basis for this 
protection is that carbamylation of acetylcholinesterase 
(AChE) prevents its reaction with the OP during a 
critical period before the available concentration of 
the latter falls to non-toxic levels; during this period, 
continuous reactivation and re-inhibition of AChE by 
the carbamate must permit sufficient activity to prevent 
toxic accumulation of acetylcholine (4). Similarly, pre-
dosing chickens with certain carbamates can protect 
against induction of OPIDN by a subsequent dose of 
neuropathic OP; this protection lasts as long as the 
half-life of carbamylated NTE (about 12 h) (12).
Much of the enigma surrounding the pathogenesis 
of OPIDN stems from the finding that compounds such 
as phenylmethanesulfonylfluoride (PMSF) and certain 
organophosphinates can also protect against OPIDN, 
even though they themselves appear to inhibit NTE for 
several days. Furthermore, neuropathic OPs undergo 
an aging reaction in which one of the alkyl/aryl groups 
is rapidly expelled from organophosphorylated NTE, 
leaving a negatively-charged adduct. This process 
renders the enzyme far more resistant to reactivation. 
However, it has been argued that the generation of 
negatively-charged adduct, rather than inhibition of 
NTE’s catalytic activity, is responsible for initiating 
OPIDN (13, 14) and that aging may induce a toxic 
gain of function in NTE (15).
On the other hand, sequential dosing with large 
amounts of a carbamate followed by PMSF does 
induce (mild) neuropathy. From this, it has been 
suggested that aging is not essential for OPIDN 
and that NTE inhibitors may have varying degrees 
of neuropathic efficacy, analogous to full and partial 
receptor agonists (16).
Inactivation of NTE initiates OPIDN
OP inhibition of NTE will, at least temporarily, 
disrupt ER phospholipid homeostasis which may 
cause general malfunction of the ER. Since this 
organelle is the starting point for all secretory 
transport in eukaryotic cells, both axonal transport 
and interaction between the axon and supporting 
glial cells will be perturbed. Inhibition of retrograde 
axonal transport has been demonstrated in OP-dosed 
chickens before the onset of ataxia (17). Abnormal 
glial-axonal/neuronal interaction is the earliest 
detected pathological change in the brains of swiss 
cheese flies (18). Distal parts of long axons may be 
most sensitive to this perturbation, as they are the 
farthest from the sources of energy and materials 
supplied by the neuronal cell body (Fig 2). The fact 
Figure 1  NTE deacylates endoplasmic reticulum-associated 
phosphatidylcholine. In this biosynthetic pathway, choline is 
converted to phosphocholine, then CDP-choline which is finally 
reacted with diacylglycerol, forming phosphatidylcholine 
(PtdCho) at the cytoplasmic face of the ER membrane. NTE 
is tethered in this location by a transmembrane segment and 
deacylates PtdCho to form soluble products, free fatty acids 
(FFA) and glycerophosphocholine (GroPCho). For more details 
see ref. (7).
Figure 2 Long axons are hypervulnerable to loss of NTE function
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that genetic knock-out of NTE and chronic TOCP 
dosing induce a similar neuropathic syndrome in mice 
is compelling evidence that the OP is indeed acting 
by inactivating NTE rather than by inducing a toxic 
gain of function.
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Sa`etak
DEGENERACIJA AKSONA I ESTERAZA POVEZANA S NEUROPATSKIM DJELOVANJEM 
ORGANOFOSFORNIH SPOJEVA - PREGLED
Ovim se kratkim pregledom razmatraju nedavna opa`anja koja upu}uju na mogu}i mehanizam odgo|ene 
neuropatije uzrokovane organofosfatima (engl. organophosphate-induced delayed neuropathy, krat.
OPIDN). Za esterazu povezanu s neuropatskim djelovanjem organofosfornih spojeva (engl. neuropathy 
target esterase, krat. NTE) dokazano je da deacilira fosfatidilkolin (PtdCho) membrane endoplazmatskog 
retikuluma (ER). Povi{ene razine PtdCho prisutne su u mozgu swiss cheese/NTE mutanta mu{ice 
Drosophila uz abnormalne membranske strukture, degeneraciju aksona i dendrita te gubitak neurona. 
Sli~na je vakuolarna patologija zamije}ena u mozgu mi{eva u kojih je obrisan NTE gen u mozgu te koji 
u starijoj dobi pokazuju klini~ke i histopatolo{ke znakove neuropatije koja je sli~na onoj u obi~nih mi{eva 
kroni~no tretiranih tri-ortho-krezilfosfatom. Odgo|ena neuropatija uzrokovana organofosfatima mogla 
bi biti posljedicom prestanka djelovanja fosfolipaze NTE, {to potom uzrokuje zatajenje endoplazmatskog 
retikuluma i smetnje u prijenosu signala putem aksona te interakcije izme|u glija i aksona.
KLJU^NE RIJE^I: endoplazmatski retikulum, fosfolipid, karbamat, mozak, organofosfat
CORRESPONDING AUTHOR:
Paul Glynn, Ph. D.
MRC Toxicology Unit, University of Leicester
Hodgkin Building
Lancaster Road, Leicester LE1 9HN, UK.
Email: pg8ºle.ac.uk
Glynn P. AXONAL DEGENERATION AND NEUROPATHY TARGET ESTERASE
Arh Hig Rada Toksikol 2007;58:355-358
